{"disease":{"id":"nash-with-fibrosis","name":"NASH with fibrosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":2},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-05221304","indication_name":"NASH with fibrosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06123858","title":"Non-alcoholic Steatohepatitis Registry Platform Study","phase":"","overall_status":"TERMINATED","enrollment_count":1122,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07502755","title":"Non-invasive Tests for Non-alcoholic Steato-hepatitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":828,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06348563","title":"AGED Diagnostics Liver Disease Assessment","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Active Genomes Expressed Diagnostics, Corp","has_results":false},{"nct_id":"NCT04366999","title":"Effectiveness of Bariatric Surgery for NAFLD/NASH","phase":"","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06111859","title":"Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification","phase":"NA","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"King's College Hospital NHS Trust","has_results":false},{"nct_id":"NCT04559126","title":"A Study of EDP-297 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Enanta Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT05461105","title":"A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hepion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05506488","title":"Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05798702","title":"Fibrosis Reduction in Non Alcoholic Steatohepatitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05737433","title":"Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Hepion Pharmaceuticals, Inc.","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}